Close Menu

NEW YORK -- Fulgent Genetics plans to offer up to $75 million of its securities, it said in a document filed with the US Securities and Exchange Commission on Monday. 

The Temple City, California-based firm has not priced its offering yet but said that it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series. 

Fulgent offers testing to clinical and research customers for hereditary genetic conditions. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.